Evidence map›Paper›PMID 22348519›Full record

ReviewJournal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance2012

The diagnosis of hypertrophic cardiomyopathy by cardiovascular magnetic resonance.

Radwa A Noureldin, Songtao Liu, Marcelo S Nacif, Daniel P Judge, Marc K Halushka, Theodore P Abraham, Carolyn Ho, David A Bluemke

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 71 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
71citing papers in PubMed, 2 pooled it
11.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

71 citing papers in PubMed, 2 syntheses or guidelines pooled it, 185 citations in OpenAlex.

  1. Native TJournal of magnetic resonance imaging : JMRI · 2018
    Pooled it
  2. Clinical outcomes associated with sarcomere mutations in hypertrophic cardiomyopathy: a meta-analysis on 7675 individuals.Clinical research in cardiology : official journal of the German Cardiac Society · 2018
    Pooled it
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

11 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Radwa A NoureldinRadiology and Imaging Sciences, National Institutes of Health Clinical Center, Bethesda, MD, USA.
Songtao Liu
Marcelo S Nacif
Daniel P Judge
Marc K Halushka
Theodore P Abraham
Carolyn Ho
David A Bluemke
Johns Hopkins University · USNational Institutes of Health Clinical Center · USBrigham and Women's Hospital · USNational Institute of Biomedical Imaging and Bioengineering · US

Funding

Molecular Biomedical Imaging Laboratory (NIBIB)ZIAEB000072 · NIBIB · NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING · PI BLUEMKE, DAVID · 2010 to 2017
$5.0M
Molecular Biomedical Imaging Laboratory (CC)ZIACL090019 · CLC · CLINICAL CENTER · PI JONES, ELIZABETH C. · 2010 to 2017
$0k
Intramural NIH HHS
6 · The paper itself

Abstract

Hypertrophic cardiomyopathy (HCM) is the most common genetic disease of the heart. HCM is characterized by a wide range of clinical expression, ranging from asymptomatic mutation carriers to sudden cardiac death as the first manifestation of the disease. Over 1000 mutations have been identified, classically in genes encoding sarcomeric proteins. Noninvasive imaging is central to the diagnosis of HCM and cardiovascular magnetic resonance (CMR) is increasingly used to characterize morphologic, functional and tissue abnormalities associated with HCM. The purpose of this review is to provide an overview of the clinical, pathological and imaging features relevant to understanding the diagnosis of HCM. The early and overt phenotypic expression of disease that may be identified by CMR is reviewed. Diastolic dysfunction may be an early marker of the disease, present in mutation carriers prior to the development of left ventricular hypertrophy (LVH). Late gadolinium enhancement by CMR is present in approximately 60% of HCM patients with LVH and may provide novel information regarding risk stratification in HCM. It is likely that integrating genetic advances with enhanced phenotypic characterization of HCM with novel CMR techniques will importantly improve our understanding of this complex disease.

Indexed as

Magnetic Resonance ImagingCardiomyopathy, Hypertrophic, FamilialContrast MediaDeath, Sudden, CardiacDisease ProgressionFibrosisGenetic Predisposition to DiseaseHumansHypertrophy, Left VentricularMyocardiumPhenotypePredictive Value of TestsPrognosisVentricular Function, LeftContrast Media

Identifiers

PMID22348519
PMCPMC3309929
OpenAlexW2098108524

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.